臨床新鮮分離緑のう菌に対するＴｏｂｒａｍｙｃｉｎ，β‐ｌａｃｔａｍ系抗菌剤およびＦｏｓｆｏｍｙｃｉｎ３剤併用の相乗効果の検討

DOI

書誌事項

タイトル別名
  • Synergistic activities of combination of tobramycin, .BETA.-lactams, and fosfomycin against freshly isolated Pseudomonas aeruginosa.

説明

The in vitro combined activities of TOB+CFS+FOM, TOB+PIPC+FOM, TOB+CPZ+FOM and TOB+CFS against fresh clinical isolates of P. aeruginosa were investigated by use of Microdilution Broth Method.<BR>1) The MICs80 of TOB, CFS, CPZ, PIPC and FOM against 201 freshly isolated P.aeruginosa were 4μg/ml, 32μg/ml, 64μg/ml, 128μg/ml and 128μg/ml, respectively.The percentage of resistant strains of TOB, CFS, PIPC, CPZ and FOM were 20%, 30%, 33.5%, 37.5% and 72.5%, respectively.<BR>2) In comparison to the combined effects in TOB+CFS+FOM, TOB+PIPC+FOM and TOB+CPZ+FOM against P.aeruginosa, TOB+CFS+FOM was superior to TOB+PIPC+FOM and TOB+CPZ+FOM, 19% of the strains showed FIC index≤0.5.<BR>3) Synergistic effect (FIC index≤0.5) of TOB+CFS was observed for 46% of the strains and the mean FIC index was 0.67.The mean FIC indices of addition of FOM 8 μg/ml or FOM 32μg/ml to TOB+CFS were 0.64 and 0.52, respectively.The synergism of TOB+CFS was enhanced by the addition of FOM 32 μg/ml.<BR>The combined therapy of TOB+CFS+FOM may be useful for serious Pseudomonas infections. The strains used in this study showed the difference of synergistic effect.To use the combination of antibiotics for the clinical field, to measure MICs of each antipseudomonas antibiotics and the synergistic effects (FIC index) may be important in routine susceptibility testing.

収録刊行物

詳細情報 詳細情報について

  • CRID
    1390001206280201472
  • NII論文ID
    130004195260
  • DOI
    10.11250/chemotherapy1953.34.294
  • ISSN
    18845894
    00093165
  • 本文言語コード
    ja
  • データソース種別
    • JaLC
    • CiNii Articles
  • 抄録ライセンスフラグ
    使用不可

問題の指摘

ページトップへ